NK cell therapy after surgery for pancreatic or bile duct cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for pancreatic or bile duct cancer within the past 12 weeks.
- Your cancer was stage II or III at the time of surgery, and the surgeon removed it completely (R0 or R1 margins).
- You are planning to receive standard chemotherapy (SLOG regimen) after surgery.
- You are generally healthy enough for daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within certain limits.
- You have had a past CMV infection (most adults have) and test negative for HIV and syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental NK cell therapy (PANK-003) given along with standard chemotherapy after surgery for solid tumors. The goal is to see if adding these immune cells can help prevent the cancer from coming back.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
Hear when a new Cholangiocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.